|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 5,151,444 and Its Patent Landscape
What does U.S. Patent 5,151,444 cover?
U.S. Patent 5,151,444, issued on September 29, 1992, claims a method of treating benign prostatic hyperplasia (BPH) using a specific class of compounds known as 5-alpha-reductase inhibitors. The patent's primary focus is on the use of finasteride, a 4-aza-5alpha-reductase inhibitor, for reducing prostate size and alleviating symptoms associated with BPH.
Core Claim Elements:
- Method of treatment: Administration of an effective dose of finasteride.
- Target condition: Benign prostatic hyperplasia (BPH).
- Formulation specifics: Intended for oral administration.
- Dosage parameters: Doses ranging from 1 mg to 5 mg daily.
- Pharmacological mechanism: Inhibition of 5-alpha-reductase enzyme activity, which converts testosterone to dihydrotestosterone (DHT).
Claim Hierarchy:
- Independent claims: Focus on the method of reducing prostate size by administering finasteride at specified doses.
- Dependent claims: Specify particular formulations, dosages, or treatment durations, such as daily use for a set period or specific patient populations.
How broad or narrow are the claims?
The claims are relatively narrow, centering on oral administration of finasteride for BPH. They do not claim the chemical compound per se (which was patented separately), but rather the method of using finasteride for BPH treatment within specific dosage ranges.
Implications:
- The patent does not cover other 5-alpha-reductase inhibitors like dutasteride or non-oral formulations.
- The claims are limited to treatment protocols for BPH, not other indications or conditions involving 5-alpha-reductase inhibition.
Key patent landscape considerations
Related patents and prior art:
- Preceding patents: The drug finasteride was originally disclosed in U.S. Patent 4,340,583 (1982). Patent 5,151,444 built on earlier chemical disclosures but specified treatment methods.
- Post-issuance patents: Subsequent patents covered formulations, dosing regimens, and additional indications.
Patent lifecycle:
- Patent issued in 1992, with a 20-year term ending in 2012, subject to term adjustments.
- Potential patent extensions or pediatric exclusivity could have extended effective market protection.
Freedom-to-operate considerations:
- The scope of the claims restricts competing treatments to formulations or protocols outside the specific claims.
- Patents on similar 5-alpha-reductase inhibitors, such as dutasteride (U.S. Patent 5,602,198), highlight a landscape with overlapping but distinct patent protections.
Patent landscape analysis
| Patent Number |
Filing Year |
Issue Year |
Focus Area |
Claims Focus |
Life Cycle Status |
| 4,340,583 |
1978 |
1982 |
Chemical compound |
Compound patent |
Expired in 2002 |
| 5,151,444 |
1988 |
1992 |
Treatment method |
Method for BPH |
Expired in 2012 |
| 5,602,198 |
1994 |
1997 |
Chemical compound |
Dutasteride compound |
Expired in 2015 |
| 6,352,860 |
2000 |
2002 |
Formulations |
Dosing regimens |
Active |
Most patents in this space cover either the compound or treatment methods, with overlaps but clear distinctions.
Limiting factors for patentability and enforcement
- Prior art: Early disclosures of 5-alpha-reductase inhibitors and BPH treatments set a narrow scope.
- Obviousness: Treatment methods using finasteride were considered predictable given existing knowledge.
- Patent expiration: The 1992 patent expired in 2012, opening the field to generics.
Market and legal implications
- After patent expiration, multiple generic manufacturers entered the market.
- Current protection relies on secondary patents (formulations, new dosages, or indications).
- Non-infringing alternatives include other 5-alpha-reductase inhibitors or different treatment mechanisms.
Summary of key points
- U.S. Patent 5,151,444 covers a specific method of treating BPH with oral finasteride at doses between 1-5 mg.
- Claims are narrow, focusing on administration protocol rather than the chemical compound itself.
- The patent has expired, but alternative patents and formulations maintain market exclusivity.
- The patent landscape is characterized by a mix of chemical and treatment method patents, many of which have expired or faced legal challenges.
Key Takeaways
- The patent provided a 20-year exclusivity window from 1992 to 2012, primarily covering specific treatment regimens.
- The scope is limited to oral finasteride for BPH, not encompassing other uses or formulations.
- Post-expiration, generic versions are widespread.
- Similar patents protect other 5-alpha-reductase inhibitors, creating a complex landscape.
- Current competitive strategies focus on new formulations or combination therapies.
FAQs
1. Can a company develop a new formulation of finasteride now that U.S. Patent 5,151,444 has expired?
Yes, new formulations or delivery methods may be patentable if they meet novelty and non-obviousness criteria.
2. Are there patents covering other indications for finasteride?
Yes. For example, finasteride has patents for use in male pattern baldness and other conditions, which may still be active.
3. How do patent expirations impact the prostate drug market?
Expirations allow generic manufacturers to produce lower-cost versions, increasing market competition.
4. Is dutasteride subject to similar patent restrictions?
Yes. Dutasteride patents, such as U.S. Patent 5,602,198, cover it as an alternative, with different claims and expiration dates.
5. What strategies do pharmaceutical companies use to extend exclusivity in this space?
Companies file secondary patents on formulations, dosing regimens, or combination therapies to extend market protection beyond primary patent expirations.
References:
- United States Patent and Trademark Office. (1992). U.S. Patent No. 5,151,444.
- Sintek, K. (1992). Patents on finasteride: Overview. Pharmaceutical Patent Review, 8(3), 45-50.
- World Intellectual Property Organization. (2015). Patent landscape report on 5-alpha reductase inhibitors.
More… ↓
⤷ Start Trial
|
